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Interleukin 9 (IL-9) is a pleiotropic cytokine that can
regulate autoimmune responses by enhancing regu-
latory CD4+FoxP3+ T regulatory (Treg) cell survival
and T helper 17 (Th17) cell proliferation. Here, we
analyzed the costimulatory requirements for the
induction of Th9 cells, and demonstrated that Notch
pathway cooperated with TGF-b signaling to induce
IL-9. Conditional ablation of Notch1 and Notch2
receptors inhibited the development of Th9 cells.
Notch1 intracellular domain (NICD1) recruited
Smad3, downstream of TGF-b cytokine signaling,
and together with recombining binding protein
(RBP)-Jk bound the Il9 promoter and induced its
transactivation. In experimental autoimmune ence-
phalomyelitis (EAE), Jagged2 ligation regulated clin-
ical disease in an IL-9-dependent fashion. Signaling
through Jagged2 expanded Treg cells and sup-
pressed EAE when administered before antigen
immunization, but worsened EAEwhen administered
concurrently with immunization by favoring Th17 cell
expansion.We propose that Notch and Smad3 coop-
erate to induce IL-9 and participate in regulating the
immune response.
INTRODUCTION
CD4+ T helper (Th) cells are crucial components of adaptive
immunity and exert their effects through the secretion of cyto-
kines. Antigen-presenting cells (APCs) are thought to determine
the fate of naive T cells by delivering three signals: signal 1 is
delivered through the T cell receptor when it engages an appro-
priate peptide-MHC complex. Signal 2 is referred to as ‘‘costi-
mulation’’ and is often equated with signaling through CD28
when it engages CD80 and/or CD86 (Keir and Sharpe, 2005).
Signal 3 refers to signals delivered from the APC to the T cell
that determine its differentiation into an effector cell. In addition
to the cytokines produced by APCs that determine the outcome
of effector T cells, a growing body of evidence suggests that
Notch pathway could be an example of a signal 3 mediatorthat can promote a broad range of differentiation processes
(Amsen et al., 2007; Amsen et al., 2004; Bassil et al., 2011;
Elyaman et al., 2007; Maekawa et al., 2003; Minter et al., 2005;
Reis e Sousa, 2006; Rutz et al., 2005; Tu et al., 2005). Notch
receptor is a cell-surface receptor with an extracellular ligand-
binding domain and a single-pass trans-membrane domain.
There are four mammalian Notch receptors (Notch1–Notch4),
all of which are expressed by CD4+ T cells and two distinct fami-
lies of Notch ligands in mammals, known as the Delta-like
ligands (consisting of DLL1, DLL3, and DLL4) and the Jagged
ligands (Jagged1 and Jagged2) (Amsen et al., 2009). Binding
of a ligand to Notch receptor results in the cleavage of the
receptor at a site in the trans-membrane portion generating
Notch intracellular domain (NICD). NICD translocates from the
plasma membrane to the nucleus where it associates with the
DNA-binding factor recombination-signal-binding protein for
immunoglobulin-k J region (RBP-Jk) (Amsen et al., 2009).
Adaptive immune responses are regulated by Th1, Th2, or
Th17 cells but also by regulatory subsets such as CD4+Foxp3+
T regulatory (Treg) cells and Tr1-interleukin-10 (IL-10)-producing
cells (Ja¨ger and Kuchroo, 2010). The Notch pathway has
emerged as an important regulator of effector and regulatory
T cell differentiation and activation (Amsen et al., 2009). Notch
can induce IL-4 by physically interacting with Gata3 transcription
factor (Amsen et al., 2007; Fang et al., 2007). Notch may also
directly activate the transcription of Tbx21 and promote Th1
cell differentiation (Minter et al., 2005). TheNotch ligand Jagged2
promotes Treg cell proliferation, leading to an increase in trans-
forming growth factor (TGF)-b production (Kared et al., 2006).
Moreover, although Notch ligand DLL4 enhances the generation
of Th17 cells by direct interaction of Notch with RORgt and Il17
promoter regions (Mukherjee et al., 2009), it also can inhibit Treg
cell development by inhibiting STAT5 transcription factor activa-
tion (Bassil et al., 2011). The Th1-Th2-Th17 cell paradigm now
includes a fourth subset of IL-9 producer effector T cells, Th9
cells (Dardalhon et al., 2008; Veldhoen et al., 2008), raising ques-
tions about the plasticity of T helper cell subsets (Locksley,
2009). Th9 cells are generated under the influence of IL-4 and
TGF-b1, but the costimulatory signals that induce Th9 cell differ-
entiation and the transcriptional regulation of these cells are not
known. Moreover, whether IL-9 mediates regulation (Eller et al.,
2011; Elyaman et al., 2009; Lu et al., 2006; Smith et al., 2011) or
sustains inflammation (Dardalhon et al., 2008; Li et al., 2010;
Nowak et al., 2009) remains controversial.Immunity 36, 623–634, April 20, 2012 ª2012 Elsevier Inc. 623
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Notch Receptors and Smad3 Induce IL-9 ProductionWe now report that Notch signaling induced by Jagged2 liga-
tion, but not Delta-like 1, promoted Th9 cell differentiation by
directly activating the transcription of IL-9. Notch1 intracellular
domain interacted with Smad3 and together bound and acti-
vated Il9 promoter at the RBP-Jk and Smad3 binding consensus
loci. When analyzing the role of IL-9 in an animal model of auto-
immune encephalomyelitis, we found that Jagged2-induced
IL-9-producing CD4+ T cells could play pro- or anti-inflammatory
roles leading to exacerbation or suppression of experimental
autoimmune encephalomyelitis (EAE) depending on the timing
of administration. Our data demonstrate that Notch costimula-
tion is required for optimal IL-9 production, but the timing of
this signal in vivo and the cytokine microenvironment determine
the outcome of clinical disease, confirming that IL-9 plays a dual
role in the regulation of immune responses.
RESULTS
Lack of Notch1 and Notch2 Signaling Impairs IL-9
Production
GATA3-deficient T cells fail to produce IL-9 when differentiated
in the presence of IL-4 plus TGF-b (Dardalhon et al., 2008).
Because Notch signaling directly regulates GATA3 expression
(Amsen et al., 2007; Fang et al., 2007), we sought to investigate
the role of Notch signaling in the differentiation of Th9 cells
in vitro. CD4+ T cells that are known to express both Notch
ligands and receptors (Figures S1A and S1B available online)
were differentiated under IL-4 plus TGF-b1 conditions for Th9
cell generation, and activation of Notch signaling was assessed
by the presence of cleaved Notch1 intracellular domain (NICD1).
We found that NICD1 was expressed during Th9 cell polariza-
tion, indicating that Notch1 signaling is activated in Th9 cells
(Figure 1A). Next, we analyzed the effects of Notch signaling defi-
ciency on the outcome of Th9 cell differentiation. Floxed Notch1
and Notch2 are expressed in naive CD4+ T cells (Amsen et al.,
2004), and deletion of Notch1 and Notch2 by polyI-polyC-
induced Mx-1 promoter-driven-Cre does not affect thymic
development (Radtke et al., 1999). Thus, we purified naive
CD4+ T cells derived from mice carrying CD4+ T cell-specific
deletions of both Notch1 and Notch2 genes (Cd4-cre Notch1fl/fl
Notch2fl/fl) and stimulated them for 4 days under Th9 or Th17
cell conditions, both of which normally induce IL-9 production
(Dardalhon et al., 2008; Elyaman et al., 2009).Cd4-cre Notch1fl/fl
Notch2fl/fl Th9 and Th17 cells produced significantly less IL-9 but
comparable amounts of IL-10, IL-13, IL-17, and IFN-g compared
to control Th9 and Th17 cells as measured by bead-based
Luminex assay (Figure 1B) and by intracellular cytokine staining
(Figure 1C). IL-4 and TGF-b gene expression were unchanged
under skewing conditions compared to WT cells (Figures 1B
and 1C), which is consistent with a previous report showing no
effect from Notch1 and Notch2 double deficiency in standard
in vitro T cell differentiation paradigm induced by the addition
of recombinant cytokines (Amsen et al., 2007). The decrease in
IL-9 production in Cd4-cre Notch1fl/flNotch2fl/fl T cells observed
when 10–25 ng/ml of IL-4 were used in combination with TGF-b1
was reversed when excessive amounts of IL-4 (100 ng/ml) was
added, suggesting that IL-4 signaling engages alternative path-
ways to compensate the deficit in Notch signaling (Figure S1C).
Given that early ablation of Notch receptors inhibits IL-9 tran-624 Immunity 36, 623–634, April 20, 2012 ª2012 Elsevier Inc.scription in Th9 cells differentiated under IL-4 plus TGF-b1
conditions, we examined whether Notch is still needed in
established Th9 cells. To address this, we polarized Cd4-cre
Notch1fl/flNotch2fl/fl or control T cells under Th9 conditions
for 4 days and subsequently infected polarized cells with
MSCV Cre-GFP retrovirus (Cre-GFP-RV) to delete Notch1 and
Notch2 receptors. Cre-positive cells were gated on the basis
of GFP expression. We found that the frequency of IL-9-positive
cells were altered by only 30% after Notch1 and Notch2
deletion, suggesting that Notch signaling is required for the
development of Th9 cells and to a lesser extent for their stabili-
zation (Figure 1D). WT CD4+ T cells were used as control so
that possible toxic effects of Cre-RV on IL-9 expression could
be ruled out.
Notch Signaling through Jagged2 Induces T Helper 9
Cell Differentiation
Notch signaling has been shown to bind and induce GATA3
transactivation (Amsen et al., 2007; Fang et al., 2007), a transcrip-
tion factor required for IL-9 production (Dardalhon et al., 2008).
We therefore questioned whether induction of Notch signaling
might regulate the production of IL-9. We tested our hypothesis
in vitro by using an antigen-specific cell differentiation in which
naive OVA-specific CD4+CD62Lhi T cells isolated by flow sorting
from spleens of naive OVA transgenic mice were exposed to irra-
diated A20 B cell lymphoma overexpressing Jagged2 or DLL1
(Kijima et al., 2008) (Figure S2A). Control cells were cocultured
with A20-mock cells. First, we found that T cells activated with
Ova peptide (0.2 mg/ml) for a week in the presence of A20-
Jagged2 cells, but not A20-DLL1 cells, produced modest
amounts of IL-9 that was suppressed when TGF-b1 was added
simultaneously in the cocultures (data not shown). However,
when naive transgenic T cells were exposed to A20-Jagged2
cells for 1 week and then stimulated again for 4 days in the pres-
ence of recombinant TGF-b1, CD4+FoxP3IL-9+ cells were
strongly induced as shown at the cellular level and by Luminex
assay, suggesting that Notch and TGF-b signaling pathways
cooperate to promote Th9 cell differentiation (Figures 2A and
2B). The presence of IL-4 in the supernatants of A20-DLL1,
A20-Jagged2, and control differentiated cells does not seem to
account for the massive induction of IL-9 per se when recombi-
nant TGF-b1 is added, given that all these cultures had compa-
rable amounts of IL-4, yet only A20-Jagged2 stimulation contrib-
utes to the differentiation of IL-9-producing cells (Figure 2A).
Because Jagged2-mediated stimulation represses IFN-g
production (Figure 2A), a negative regulator of IL-4 plus TGF-
b1-mediated Th9 cell differentiation (Schmitt et al., 1994), we
investigated the possibility that Jagged2 signaling indirectly
promotes Th9 cell development by attenuating IFN-g produc-
tion. Thus, IFN-g neutralizing antibody was added to Ova trans-
genic cells cocultured with A20-mock cells during the first and
second rounds of stimulation. We found that IFN-g neutralization
per se did not promote Th9 cell differentiation, although it
enhanced the production of IL-9 under Jagged2 plus TGF-b1
stimulation, indicating that Jagged2-induced IL-9 is IFN-g inde-
pendent (Figure S2B). It is noteworthy that Jagged2 signaling
alone increases the frequency of Treg cells (Figure 2B), which
is in agreement with previously reported findings in mouse cells
(Kared et al., 2006). To further demonstrate the involvement of
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Figure 1. Notch1 and Notch2 Receptors Are Required for Optimal Production of IL-9
(A) Immunoblot analysis of cleaved Notch1 intracellular domain (NICD1) in naive CD4+CD62Lhi T cells 24 hr after differentiation under Th1, Th2, Th9, and Th17 cell
conditions and inducible Treg cell (TGF-b) conditions.
(B) Naive CD4+ T cells were isolated from N1N2 double-deficient mice (Notch1fl/flNotch2fl/fl Cd4Cre) or control (Notch1fl/flNotch2fl/fl) littermates and stimulated
in vitro under Th9 and Th17 cell conditions. After 4 days, IL-9, IL-10, IL-13 (upper panel), IL-17, and IFN-g (middle panel) productionwasmeasured by bead-based
Luminex assay and IL-4 and TGF-b1 gene expression (lower panel) was assessed by quantitative RT-PCR.
(C) Intracellular staining for IL-4, IL-9, and IL-17 in naive control and Cd4-cre Notch1fl/flNotch2fl/fl. CD4+ T cells differentiated for 4 days under Th9 and Th17 cell
conditions and stimulated with PMA and ionomycin for 4 hr. Numbers in outlined areas indicate percent of positive cells.
(D) Naive CD4+ T cells were isolated from Notch1fl/flNotch2fl/fl or WT syngenic mice and cells were differentiated under Th9 cell conditions followed by cell
infection with supernatants containing MSCV Cre-GFP-RV to delete Notch1 and Notch2 receptors. Cre-Transduced cells were gated based on the GFP
expression (y axis) and IL-9 expression (x axis) wasmeasured by intracellular staining using flow cytometry. Data are representative of at two to three independent
experiments. **p < 0.01; ***p < 0.0005. Error bars represent SEM.
Immunity
Notch Receptors and Smad3 Induce IL-9 ProductionNotch in IL-9 production, we took advantage of floxed NICD1
(NICD1fl/fl) transgenic mice carrying 10–20 copies of the NICD1
transgene that is prevented by a ‘‘Lox-STOP-Lox’’ cassette
(Yang et al., 2004). Naive CD4+ T cells were prepared from the
spleens of these mice and cultures were transduced with Cre-
GFP-RV. We used WT cells as controls to rule out possible
toxicity or off-target effects of Cre DNA and transduced the
cells with Cre-GFP-RV. We found thatNICD1fl/fl cells transduced
with Cre-RV, as determined by the GFP expression by flow
cytometry, exhibited a significant increase in IL-9-positive cells
compared to control cells (11-fold) and this was further
enhanced when transduced NICD1fl/fl cells were exposed to
recombinant TGF-b1 (Figure 2C).Jagged2 Enhances TGF-b-Induced Smad3 Signaling
TGF-b is crucial for the differentiation of human and mouse Th9
cells (Beriou et al., 2010; Dardalhon et al., 2008). TGF-b signaling
induces the phosphorylation of Smad3 that translocates into the
nucleus and, in a cooperative manner with other nuclear cofac-
tors, regulates the transcription of target genes. To investigate
a possible crosstalk between Jagged2-Notch and TGF-b
signaling, we analyzed the expression of phospho-Smad3 in
flow cytometry-sorted CD4+ T cells exposed to recombinant
TGF-b1 in the presence of soluble Jagged2-Fc fusion protein
or control IgG. Indeed, we found that Jagged2-Fc induces
accumulation of phospho-Smad3 within 60 min after treatment
(Figure 3A). The comparable increase in total Smad3 in responseImmunity 36, 623–634, April 20, 2012 ª2012 Elsevier Inc. 625
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Figure 2. Effects of Notch Ligands on IL-9
Production
(A and B) Flow cytometer sorted naive CD4+CD62Lhi
T cells isolated from spleens of naive Ova-TCR trans-
genic BALB/c (DO11.10) mice were cocultured with
irradiated A20 B lymphoma cells (2:1 ratio) over-
expressing Jagged2, DLL1, or mock control. Cultures
were stimulated with Ova peptide (0.2 mg/ml) for up to
1 week in the presence or absence of TGF-b1 (1 ng/ml),
live cells were purified with a dead cell removal kit
(Miltenyi); purification was followed by a second
round of polyclonal activation with immobilized Abs
against CD3 (1 mg/ml) and CD28 (1 mg/ml) for 4 days.
Cytokine production was measured by (A) Luminex
assay and by (B) intracellular staining and analyzed by
flow cytometry.
(C) CD4+ T cells were prepared from the spleens of
NICD1fl/fl transgenic or WT mice and cultures were
transduced with retroviral particles expressing Cre-
GFP recombinase. Transduced cells were gated on the
basis of the GFP expression, and IL-9+ (x axis) and
IL-17+ (y axis) T cells were assessed by flow cytometry.
Addition of recombinant TGF-b1 to NICD1fl/fl trans-
duced cells for additional 2 days increased the
frequency of IL-9+ cells. Assays were carried out in
triplicates and data are representative of two to three
independent experiments. *p < 0.05; **p < 0.01;
***p < 0.0005. Error bars represent SEM.
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Notch Receptors and Smad3 Induce IL-9 Productionto Jagged2-Fc stimulation 60 and 120 min after treatment indi-
cates that the Jagged2-Notch regulates the protein expression
of Smad3 rather than acting at the level of phosphorylation.
To study whether Notch signaling positively regulates the
stabilty of Smad3 protein, we overexpressed NICD1 in primary
CD4+ T cells isolated from floxed-NICD1 transgenic mice.
T cells were transduced with Cre-RV to induce the expression
of NICD1. Control cells were transduced with an empty vector.
Cells were then activated with anti-CD3 and anti-CD28 in the
presence of the protein synthesis inhibitor cycloheximide626 Immunity 36, 623–634, April 20, 2012 ª2012 Elsevier Inc.(CHX) to block new protein synthesis and
Smad3 protein expression was analyzed by
immunoblot. We found that Smad3 protein
loss was much less prominent in T cells over-
expressing NICD1, suggesting that NICD1
induces stabilization of Smad3 (Figure 3B).
Moreover, we demonstrated a physical
interaction between Smad3 and NICD that
was enhanced in the presence of TGF-b1.
Human embryonic kidney 293T cells were
cotransfected with Flag-Smad3 and myc-
NICD1 constructs and were cultured for
24 hr. Smad3 was immunoprecipitated with
anti-Flag M2 and immunoblots were probed
with anti-NICD1. We detected the presence
of NICD1 in the immunoprecipitates and
this association between Smad3 and NICD1
was further enhanced in response to
TGF-b1 treatment, suggesting that TGF-b1
promotes the stabilization of the NICD1-
Smad3 complex (Figure 3C). We confirmedthe interaction between endogenous Smad3 and NICD1 coim-
munoprecipiated from cultured Th9 cells that were differentiated
under IL-4 plus TGF-b1 conditions, suggesting that the physical
interaction can occur at physiological expression (Figure 3D).
Because our data demonstrate that Notch regulates TGF-
b-Smad3 signaling, we examined whether TGF-b regulates
Jagged2 expression in T cells and dendritic cells (DCs). We puri-
fied naive CD4+CD62LhiFoxP3 T cells and splenic DCs from
naive mice and cells were treated with recombinant TGF-b1
for 24 hr. We found that addition of recombinant TGF-b1
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Figure 3. Crosstalk Between Smad3 and Notch Signaling
(A) Immunoblot of phospho-dependent and -independent Smad3 in Naive CD4+CD62Lhi stimulated with anti-CD3/CD28 (1 mg/ml) and recombinant TGF-b1
(5 ng/ml) in the presence of Jagged2-Fc (J2; 5 mg/ml) or control Ig (5 mg/ml). b-actin was used as internal control for protein loading.
(B) Immunoblot of Smad3 expression in T cells overexpressing NICD1. CD4+ T cells were isolated from spleens ofNICD1fl/fl transgenic micewere transducedwith
Cre-RV to induce the expression of NICD1. Control cells were transduced with an empty vector. Cells were then activated with anti-CD3 and anti-CD28 (1 mg/ml)
in the presence of the protein synthesis inhibitor cycloheximide (CHX) (50 mg/ml) to block new protein synthesis and Smad3 protein expression was analyzed by
immunoblotting. NICD1 and b-actin expression is shown.
(C) Coimmunoprecipitation of Flag-Smad3 and myc-NICD1 in 293T lysates. 293T cells were cotransfected with Flag-Smad3 and myc-NICD1 constructs, cells
were either left untreated for 24 hr or were exposed to recombinant TGF-b1 (5 ng/ml) for 6 hr before lysis, and anti-Flag-Smad3 or IgG immunoprecipitates (IP)
were subjected to immunoblot analysis (IB) with myc antibody as described in the Experimental Procedures.
(D) Coimmunoprecipitation of endogenous Smad3 and NICD1 in Th9 cells. Naive CD4+ T cells were differentiated under Th0 or Th9 cell conditions for 48 hr and
lysates were immunoprecipitated with Smad3 antibody or isotype control IgG and immunoblotted with NICD1 or Smad3 antibody as indicated.
(E) Taqman PCR for relative expression of Jagged2 in CD4+CD62Lhi Foxp3 cells (left panel) and dendritic cells (DCs) (right panel) exposed to recombinant
TGF-b1 for 12 and 24 hr, respectively. Ig, control IgG; J2, Jagged2-Fc fusion protein.
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Notch Receptors and Smad3 Induce IL-9 Productionupregulated Jagged2 mRNA levels in both CD4+ T cells and DCs
(Figure 3E).
Notch1, RBP-Jk and Smad3 Cooperate to Transactivate
the Il9 Promoter
Because addition of TGF-b1 enhances the differentiation of Th9
cells by Jagged2 (Figure 2), we hypothesized that the transcrip-
tion factors downstream of Notch and TGF-b signaling might
transactivate Il9 promoter in Th9 cells. To investigate this, wesearched the Il9 promoter for potential candidates and found
two potential binding sites for RBP-Jk and Smad3 on the Il9
promoter (Figure S3A). To determine whether RBP-Jk and
Smad3 can bind the Il9 promoter, we used chromatin immuno-
precipitation (ChIP) techniques to study the interaction between
these transcription factors and Il9 promoter. Primer sets flanking
the RBP-Jk and Smad3 binding regions on Il9 were designed to
amplify the immunoprecipitated ChIP DNA by qPCR. Naive
CD4+CD62Lhi Cd4-cre Notch1fl/flNotch2fl/fl or control T cellsImmunity 36, 623–634, April 20, 2012 ª2012 Elsevier Inc. 627
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Notch Receptors and Smad3 Induce IL-9 Productionwere differentiated under Th9 cell polarization condition for
4 days and then analyzed by ChIP. We detected binding of
RBP-Jk and Smad3 to their respective binding sites in the Il9
promoter in Th9 cells (Figure 4A). We next investigated
whether the interaction between NICD1 and Smad3 occurs at
the Il9 promoter level. We found that NICD1 and Smad3 form
a complex at both RBP-Jk and Smad3 binding sites in the Il9
promoter (Figure 4A). Notably, lack of Notch1 and Notch2 recep-
tors in Th9 cells inhibited the binding of both RBP-Jk and Smad3
to the Il9 promoter, suggesting that Notch downstream signaling
is required for physical interaction of Smad3 with the Il9
promoter (Figure 4A). We confirmed the specificity of RBP-Jk
and Smad3 binding by amplifying a region of the Il9 promoter
that does not contain RBP-Jk or Smad3 binding sites (Figures
S3B and S3C).
In order to assess whether RBP-Jk specifically binds to the Il9
promoter only in Th9 cells, we differentiated naive CD4+ T cells
into Th1, Th2, Th9, and Th17 cells and measured RBP-Jk and
Smad3 binding to their respective binding sites within the Il9
promoter with ChIP assays. Indeed, we found that RBP-Jk and
Smad3 binding was detected in Th9 cells with weak binding in
the other T helper cell types (Figure 4B). We further evaluated
the specificity of the cooperation between Notch and Smad3 in
Th9 cells by analyzing their binding to Gata3 promoter, which
contains RBP-Jk and Smad3 binding motifs. We found that
although there was detectable binding of RBP-Jk to the Gata3
promoter in differentiated Th9 cells, we did not detect any
binding of Smad3 to the Gata3 promoter, suggesting that
RBP-Jk and Smad3 specifically bind solely to the Il9 promoter
(Figures S3D and S3E). We next studied whether chromatin
modifications at the RBP-Jk and Smad3 binding sites within
the Il9 promoter could explain the induction of IL-9 by Jagged2
and TGF-b1. We found that Th9 cells differentiated for 4 days
exhibited high histone 3 (H3) and H4 acetylation at the RBP-Jk
and Smad3 sites as analyzed by ChIP followed by qPCR, which
is consistent with the simultaneous recruitment of NICD1-
Smad3 complex to the RBP-Jk and Smad3 binding sites (Fig-
ure 4C). Concordant with their high expression of IL-9, we found
that Th9 cells showed substantially increased permissive H3
lysine 4 monomethylation (H3K4me1) modifications in the
RBP-Jk and Smad3 binding sites in the Il9 promoter with notably
decreased repressive H3 lysine 27 trimethylation (H3K27me3)
chromatin modifications compared to Th17 cells on day 4 after
in vitro polarization (Figure 4D). Intriguingly, Th17 cells exhibited
a different pattern of chromatin modifications at the RBP-Jk and
Smad3 binding sites in that H3K4me1 and H3K27me3marks are
colocalized, which is an indication of bivalent domains (Fig-
ure 4D), a signature that has been associated with low levels of
transcription and are thought to poise genes for activation or
repression during T cell differentation (Wei et al., 2009).
To analyze the functional relevance of the binding of RBP-Jk
and Smad3 to their target sequences in Il9, we investigated the
ability of RBP-Jk and Smad3 to transactivate the Il9 promoter
in reporter assays. We used reporter constructs pGL3-Il9, con-
taining the firefly luciferase gene under the control of the Il9
promoter. Cotransfection of the pGL3-Il9 luciferase reporter
construct with a plasmid encodingNICD1 resulted in a significant
increase in Il9 transcription (Figure 4E). The Il9 promoter activity
was further amplified when NICD1 and RBP-Jk plasmids were628 Immunity 36, 623–634, April 20, 2012 ª2012 Elsevier Inc.cotransfected and reached a higher level in the presence of
Smad3 plasmid, suggesting that Notch and Smad3 pathways
cooperate to control the transcriptional activity of Il9 promoter
(Figure 4E). These findings were confirmed in 293T cells, in which
plasmids encoding NICD1 with RBP-Jk in combination with
a constant amount of Il9 promoter luciferase construct resulted
in a significant induction of Il9 promoter transactivation (Fig-
ure S3F). The cooperation between Notch and Smad3molecules
is specific for the Il9 promoter given that the activity of Il4
promoter was not modulated by the cotransfection of both
NICD1 and Smad3 in 293T cells (Figure S3G). Finally, to demon-
strate that activation of the Il9 promoter by RPB-Jk and Smad3
requires binding to their consensus binding motifs, we induced
mutations of the Il9-Luc reporter constructs. RPB-Jk-binding
site (GTGGGA) was replaced by (GTGAAA) and Smad3-binding
site (GTCTG) was replaced by (ACCTG) with a site-directed
mutagenesis approach. This resulted in the abrogation of Il9
promoter activation indicating that the regulation of Il9 promoter
activity was specific for these binding sites (Figure 4E).
Context-Dependent Regulation of Treg/Th17 Cell Ratio
in EAE by IL-9
We have recently shown that IL-9 enhances the suppressive
activity of Treg cells and that IL-9 receptor deficient mice had
exacerbated EAE (Elyaman et al., 2009). We sought to investi-
gate the consequences of Jagged2 ligation in EAE, a ligand
constitutively expressed on T cells and APCs and downregu-
lated on myeloid cells during EAE (Figure S1A). Taking into
consideration that transgenic mice overexpressing TGF-b
develop severe EAE after immunization with MOG35–55 peptide
in CFA (CFA immunization induces IL-6) via the induction of
Th17 cell responses (Bettelli et al., 2006; Korn et al., 2008), and
that Jagged2 ligation expands FoxP3 regulatory T cells as shown
in Figure 2B, we designed two protocols for Jagged2 ligation
therapy in EAE. We used a signaling anti-Jagged2 monoclonal
antibody (clone HMJ2-1) (Fukushima et al., 2008) that activates
RBP-Jk as demonstrated by using a reporter assay (Figure S4A).
C57BL/6 WT mice received Jagged2 antibody in a pretreatment
protocol starting 5 days before MOG35-55 + CFA for eight doses
every other day or a concurrent treatment protocol starting on
the day of MOG35-55 + CFA immunization for five consecutive
doses. As expected, we found that both regimens expanded
Treg cells, causing increase in total TGF-b (acid-treated) (Figures
S4B–S4E) and IL-9 production (Figures 5B and 5E) but had
opposite outcomes on disease depending on the inflammatory
milieu: when administered before immunization, Jagged2 anti-
body suppressed EAE compared to IgG-treated mice (mean
maximal grade for IgG control mice 2.8 ± 2.3; Jagged2 group
1 ± 0.3, p < 0.05; Figure 5A). Enumeration of Treg and effector
T cells (Th17) showed an increase in the Treg/Th17 cell ratio in
the Jagged2 pretreated mice compared to control IgG mice
(Figures 5C and S4B). This disease protection was reversed
when mice received anti-Jagged2 in the presence of anti-IL-9
blocking antibody (mean maximal grade for Jagged2 group
1 ± 0.3 compared to Jagged2 + anti-IL-9 2.3 ± 0.3, p < 0.05; Fig-
ure 5A) and the Treg/Th17 cell balance was tipped in favor of
Th17 cells (Figure 5C).
In contrast, anti-Jagged2 administration concurrently with
MOG35-55 + CFA immunization exacerbated significantly the
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Figure 4. Notch1, RBP-Jk and Smad3 Bind and Activate Il9 Promoter
(A) Notch1fl/flNotch2fl/fl or Cd4-cre Notch1fl/flNotch2fl/fl splenic CD4+CD62Lhi T cells were purified by flow cytometry and stimulated under Th9 cell conditions for
4 days and fixed for ChIP. Abs used for IP are anti-Notch1, anti-RBP-Jk, and anti-Smad3. Total input DNA before IP was used for normalization of data. The
graphs represent quantitative PCR analysis of the ratio of enriched Il9 promoter with RBP-Jk (left panel) or Smad3 (right panel) binding sites to the input DNA.
RBP-Jk and Smad3 binding sites were amplified with Il9-specific promoter primers.
(B) ChIP analysis of RBP-Jk (left panel) and Smad3 (right panel) binding to the Il9 promoter in naive CD4+ cells differentiated for 3 days under Th1, Th2, Th9, and
Th17 cell polarization conditions. Data are presented as average ± SE of percent input with subtraction of control IgG.
(C) ChIP analysis of histone H3 and H4 acetylation (Ac) at the RBP-Jk (left panel) and Smad3 (right panel) binding sites within the Il9 promoter in Th9 cells. IgG
was used as negative control for anti-AcH3 and AcH4 antibodies and total input DNA before IP was used for normalization of data.
(D) ChIP analysis of H3K4me1 and H3K27me3modifications normalized to input controls at the RBP-Jk (left panel) or Smad3 (right panel) binding sites in Th9 and
Th17 cells differentiated in vitro for 4 days.
(E) Primary CD4+ T cells were transfected by electroporation with a constant amount of pGL3-Il9, pGL3-Il9-RPB-Jkmutant, or pGL3-Il9-Smad3mutant vectors in
the presence of the indicated constructs, cells were activated with PMA/Ionomycin for 24 hr, cell protein extracts were prepared, and luminescence was
measured. Data represent mean ± SE of a representative experiment each performed in triplicate. **p < 0.01; ***p < 0.001. Error bars represent SEM.
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Figure 5. Opposite Roles of Jagged2 Signaling in EAE and Regulation by IL-9
(A and D) Disease score of C57BL/6 WT mice that were immunized with 50 mg MOG35–55/CFA and received either eight doses (8 3 250 mg, n = 6) of Jagged2
signaling antibody or IL9 blocking antibody (A, pretreatment) every second day starting from 5 days before immunization or five doses (5 3 250 mg, n = 6)
concurrent withMOG35–55/CFA immunization (D, concurrent treatment). Control mice received IgG treatment according to the same regimen of each experiment.
(B and E) Luminex assay of IL-9 production from splenocytes of immunized mice activated with MOG35–55 (10 mg/ml) for 48 hr.
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Notch Receptors and Smad3 Induce IL-9 Productionclinical disease (mean maximal grade IgG-treated mice 2.5 ± 0.2
comparedwith Jagged2 group 3.5 ± 0.2, p < 0.01; Figure 5D) and
decreased the Treg/Th17 cell ratio (Figure 5F). This was IL-9
dependent given that IL-9 neutralization with IL-9 blocking anti-
body reversed the encephalitogenicity of Jagged2 antibody
(mean maximal grade Jagged2 + anti-IL-9-treated mice 2.1 ±
0.1 compared with Jagged2 group 3.5 ± 0.2, p < 0.005; Fig-
ure 5D) and increased the Treg/Th17 ratio (Figure 5F). Minimal
effects on the cytokine and disease outcome were observed
when IL-9 antibody was administered alone under the two proto-
cols (Figures 5A–5F). To assess the specificity of Jagged2-
induced IL-9 production in the induction of opposite outcomes
of EAE, we decided to block IL-4, a Th2 cytokine that is induced
by Jagged2 ligation. Thus, we used IL-4 blocking antibody to
neutralize IL-4 inmice that received early or concurrent regimens
of Jagged2 signaling antibody. We found that inhibition of IL-4 in
mice that received Jagged2 antibody worsened the clinical
disease, and that was independent of the time of the treatment
(Figure S4F). These data suggest that dual effects of Jagged2
signaling in EAE are specific for IL-9.
To demonstrate that Notch signaling regulates directly IL-9
production in EAE, we immunized Cd4-cre Notch1fl/flNotch2fl/fl
or control Notch1fl/flNotch2fl/fl mice with MOG35–55 + CFA, and
cytokine production was analyzed on day 10 after immunization.
Additional groups of immunized mice were used for monitoring
the clinical disease outcome.We found that mice lacking Notch1
and Notch2 receptors develop mild EAE compared to control
mice (mean maximal grade Notch1fl/flNotch2fl/fl mice 2.5 ± 0.3
compared with Cd4-cre Notch1fl/flNotch2fl/fl group 0.4 ± 0.2,
p < 0.01; Figure 5G). Cytokine production was measured by
Luminex of draining lymph node cells that were isolated
10 days after immunization and were challenged with MOG35–55
peptide for 2 days. We found that Cd4-cre Notch1fl/flNotch2fl/fl
mice exhibit defect in IL-9 production and this was associated
with lower IL-17 levels (Figure 5H). However, Treg cell frequency
was not affected in Cd4-cre Notch1fl/flNotch2fl/fl mice (data not
shown).
DISCUSSION
Notch signaling is readily activated in Th9 cells as shown by the
expression of NICD1 and by abolished differentiation of Th9 cells
in conditional ablation of Notch receptors, indicating that Notch
signaling is required for the induction of murine Th9 cells. In the
context of T cell differentiation and activation, Notch pathway
represents a ‘‘signal 3’’ mediator that can promote a broad range
of T cell differentiation processes. Here, we show that Jagged2
but not Delta-like 1 was able to reprogram naive T cells into
‘‘pre-Th9 cells’’ that switch to mature IL-9 producers in the pres-
ence of TGF-b. Moreover, T cells lacking Notch1 and Notch2
receptors had weak Th9 cell differentiation, supporting the(C and F) Ratio of CD4+FoxP3+ Treg and Th17 cells isolated from lymphoid tissue
Treg/Th17 cells per individual mouse. Data are representative of two independen
antibodies injections.
(G and H) Disease score and cytokine profile of Cd4-cre Notch1fl/flNotch2fl/fl and c
every second day followed by immunization with 50 mg MOG35–55/CFA. Lymph
MOG35–55 (10 mg/ml) for 48 hr, and cytokine production was measured by Lumin
represent SEM.idea that costimulation is required for proper activation of all
T cell subsets for entry into effector cell differentiation programs.
Bioinformatic analysis has led us to discover the molecular
interaction between TGF-b and Notch pathways and the binding
of Smad3 and RBP-Jk to the Il9 promoter. We found that Smad3,
a downstream effector of TGF-b signaling, recruits NICD1 under
Th9 cell differentiation conditions and binds the Il9 promoter and
together induce its activation. Th9 cells are critically dependent
on the transcription factor GATA3 and its expression is neces-
sary but not sufficient for Th9 cell differentiation (Dardalhon
et al., 2008). Notch has been shown to interact with GATA3
and induces its activation; thus, we do not rule out a role for
GATA3 in the induction of IL-9 by Notch signaling. Nonetheless,
our data demonstrate clearly that Notch binds the Il9 promoter
directly and induces its activation. The fact that large amounts
of recombinant IL-4 were able to compensate for loss of Notch
signals in driving IL-9 production in vitro suggests that in the
absence of Notch, strong IL-4 stimulation drives the expression
of an alternative pathway that can rescue the defect in IL-9
production. The important role of Notch and Smad3 signaling
in the generation of Th9 cells was further supported by the chro-
matin modifications signature at the RBP-Jk and Smad3 binding
sites in the Il9 promoter in that H3 and H4 acetylation was
increased in addition to a notable upregulation in permissive
H3K4me1 and downregulation in repressive H3K27me3 to
same regions compared to Th17 cells.
The biological effects of TGF-b1 under inflammatory condi-
tions on effector and memory T cells are much less understood.
TGF-b1 has opposite effects on naive versus memory murine
CD4+ T cells: TGF-b1 alone can promote the production of signif-
icant amounts of IL-9 when added to memory CD4+ T cell
cultures, but it fails to induce IL-9 in naive CD4+ T cells (data
not shown), suggesting differential transcriptional requirements
for IL-9 induction in naive versus memory T cells. Although we
find that activation of Notch signaling by Jagged2 induces rapid
stabilization and accumulation of phosphorylated Smad3
(60 min), Jagged2 treatment did not translate into a strong
Th9 cell phenotype. The exact reason behind this observation
is not clear but could be attributed to the fact that TGF-
b-Smad3 signals can inhibit T cell activation and their effector
cell functions (Attisano and Wrana, 2002). Indeed, we found
that cells exposed to Jagged2 alone do not show accelerated
proliferation compared to control cells. However, when TGF-
b-Smad3 signal is turned on by the addition of recombinant
TGF-b1 into Jagged2-pretreated T cell cultures, ‘‘pre-Th9 cells’’
expressing effector memory markers, CD4+CD44hiCD62L,
(data not shown), these cells were converted into fully differenti-
ated Th9 cells. These data are in agreement with the recent work
from our group and others where addition of TGF-b1 alone to
human memory T cells switched them into Th9 cells (Beriou
et al., 2010; Wong et al., 2010). In line with these observations,s of treated mice on day 10 after immunization. Each dot represents the ratio of
t experiments. Capped lines under the x axis in (A) and (D) indicate the days of
ontrolNotch1fl/flNotch2fl/fl mice that received four injections of PolyI:C (300 mg)
nodes were isolated 10 days after immunization, cells were activated with
ex. DPI, days postimmunization. *p < 0.05; **p < 0.01; ***p < 0.001. Error bars
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Il9 promoter transactivation, whereas cotransfection of Smad3
and NICD1-RBP-Jk converted these repressors into activators
of Il9 promoter. Moreover, we show that TGF-b1 stabilizes the
complex NICD1-Smad3, which is in agreement with a previous
study in myoblasts cells (Blokzijl et al., 2003), and this further
emphasizes the cooperation of Notch and TGF-b pathways in
the induction of Th9 cells. The physical interaction between
NICD1 and Smad3 and the rapid nature of Notch-induced
Smad3 accumulation (1 hr) suggests that Notch cooperation
with Smad3 signaling is an early event that occurs in the cytosol
before inducing Il9 transcription at the promoter level, although
this cooperation continues in the nuclear compartment where
Notch and Smad3 complex is detected at both RBP-Jk and
Smad3 binding sites.
TGF-b is a pleiotropic cytokine that exerts tolerogenic proper-
ties by inducing Treg cells and antagonizing Th1 cell develop-
ment, but it also promotes the development of Th17 cells in
the context of inflammatory milieu in which IL-6 is produced
(Bettelli et al., 2006). The role of IL-9 in autoimmunity has been
controversial, and it is unclear whether IL-9 plays a pro- or an
anti-inflammatory role. Our present study highlights a dual role
of IL-9 during an inflammatory response in vivo, which may
explain the discrepancies between recent studies dealing with
IL-9 (Dardalhon et al., 2008; Eller et al., 2011; Elyaman et al.,
2009; Lu et al., 2006; Nowak et al., 2009). The role of TGF-b in
invoking IL-9 production from T cells was originally reported by
Schmitt et al. (1994). Over a decade later, regulatory CD4+
T cells were shown to produce IL-9 that plays a regulatory role
in mediating graft tolerance by a mast cell-dependent process
(Lu et al., 2006). Recently, we showed that IL-9 is produced by
proinflammatory Th9 and Th17 cells (Dardalhon et al., 2008;
Elyaman et al., 2009), and although adoptive transfer of Th9 cells
induces colitis in Rag-deficientmice (Dardalhon et al., 2008), IL-9
plays a regulatory role in vitro and in mouse models of inflamma-
tory diseases by enhancing the suppressive activity of FoxP3+
Treg cells and recruitment of mast cells (Eller et al., 2011;
Elyaman et al., 2009; Feng et al., 2011; Stephens et al., 2011).
Moreover, Th17 cells deficient in IL-9 expression are more path-
ogenic in autoimmune gastritis (Stephens et al., 2011). It is
intriguing that IL-23 stabilizes Th17 cells to make them more
pathogenic, and also downregulates IL-9 production by Th17
cells (Elyaman et al., 2009; Ja¨ger et al., 2009), which is in agree-
ment with a protective role of IL-9. To add more complexity to
this issue, a recent study showed that IL-9 produced by Th17
cells is proinflammatory (Nowak et al., 2009). Here, we demon-
strate that Jagged2-mediated IL-9 production plays anti- or
pro-inflammatory roles in EAE depending on the timing and
context of inflammatory conditions by altering the Treg/Th17
cell ratio. Indeed, using two different regimens of Jagged2 anti-
body administration, we found that mice that received the
protective Jagged2 pretreatment regimen exhibited an increase
in the Treg/Th17 cell ratio leading to amelioration of the clinical
disease and suppression of proinflammatory cytokines, all of
which were reversed by neutralizing IL-9. On the other hand,
when anti-Jagged2 therapy was delivered concurrent with
MOG35–55 + CFA-immunization (a strong source of IL-6), the
Treg/Th17 cell ratio was reversed in favor of Th17 cells abun-
dance, leading to an exacerbation of clinical disease, which632 Immunity 36, 623–634, April 20, 2012 ª2012 Elsevier Inc.was also reversed by the use of anti-IL-9 neutralizing therapy.
This could be explained by the fact that the expansion of Treg
cells promotes an increase in TGF-b production and when this
is concurrent with IL-6 production, it creates ideal conditions
for Th17 cell generation, which are further enhanced by
Jagged2-mediated increase in IL-9. These findings are in agree-
ment with recent data demonstrating an important role of IL-9 in
promoting Th17 cells (Elyaman et al., 2009; Nowak et al., 2009). It
should be noted that IL-9 was initially characterized as a T cell
growth factor, suggesting that the effects of anti-IL-9 on Treg
and Th17 cells could be attributed to a decrease in T cell survival
and activation. In agreement with this hypothesis, transgenic
mice overexpressing IL-9 have increased incidence of thymic
T cell lymphomas, suggesting that deregulated IL-9 expression
could be involved in the development of some T cell malignan-
cies (Renauld et al., 1994; Uyttenhove et al., 1991).
In conclusion, our results highlight the pleiotropic effects of
IL-9 in immune responses and its dual role in regulating auto-
immunity. We propose that the initiation and progression of
organ damage in complex disease are dependent on the timing
of cytokine signals in relation to the triggering event.
EXPERIMENTAL PROCEDURES
Mice and EAE Induction with MOG35–55
Female 6- to 8-week-old C57BL/6 and Ova-Tg BALB/c (DO11.10) mice were
purchased from the Jackson Laboratory (Bar Harbor, Maine). FoxP3.GFP
knockin (foxp3.gfp.KI) mice were generated as described (Korn et al., 2007).
Notch1Notch2fl/fl and Mx-Cre mice were generated as previously described
(Radtke et al., 1999). NICD1fl/fl transgenic mice (Yang et al., 2004) were
purchased from Jackson laboratory. MOG35–55 peptide (M-E-V-G-W-Y-R-S-
P-F-S-R-O-V-H-L-Y-R-N-G-K) corresponding to the mouse sequence was
synthesized in the Biopolymer Laboratory (University of California, Los
Angeles, California). Mice were immunized subcutaneously in the flanks with
50–75 mg of MOG35–55 peptide + CFA as described previously (Elyaman
et al., 2007) and were scored as follows: grade 1, limp tail or isolated weakness
of gait without limp tail; grade 2, partial hind and front leg paralysis; grade 3,
total hind leg; grade 4, total hind leg and partial front leg paralysis; and grade
5, moribund or dead animal. All animal experiments were done in compliance
with the approval of the Harvard Medical Area Standing Committee on
Animals.
Antibodies and Reagents
The generation and characterization of hamster IgG mAb specific for
mouse Jagged2 (HMJ2-1) were described previously (Fukushima et al.,
2008). Anti-IL-9 (MM9C1) is a mouse anti-mouse neutralizing antibody
(Richard et al., 2000). Anti-IL-4 is a rat anti-mouse neutralizing antibody.
These antibodies weremanufactured byBioxcell andwere given intraperitone-
ally (i.p.) at 250 mg starting at day 5 before immunization (pretreatment
regimen) or at the day of immunization (concurrent treatment regimen) every
second day till day 10 postimmunization unless otherwise indicated. Control
hamster, mouse, or rat IgG antibodies were given in accordance with the
same protocol. Notch ligands Fc fusion proteins were purchased from R&D
Systems.
In Vitro T Cell Differentiation, Luminex Assay, Flow Cytometry
Staining, Immunoblotting, Co-IP, and RT-PCR
For the above methods, see Supplemental Experimental Procedures.
ChIP and qPCR
CD4+CD62Lhi naive T cells were purified by FACS sorting and were induced
toward Th9 and ChIP was performed with ChampionChip kit (SABiosciences).
Cell lysates were used for immunoprecipitation with anti-RBP-Jk (Cosmo Bio,
Japan), anti-Smad3 (Cell Signaling), anti-Notch1 (Santa Cruz Biotechnology),
Immunity
Notch Receptors and Smad3 Induce IL-9 Productionanti-H3K4me1 and anti-H3K27me3 (Active Motif), or anti-acetylated histone
H3 and H4 (Millipore) and were compared to control IgG. One region of the
Il9 promoter containing putative RBP-Jk and Smad3 binding sites was ampli-
fied by SYBR Green qPCR (Roche) and quantified in triplicate with the percent
of input method. The following primers were used: Il9/Smad3 (50-AGTCCAGA
CAGCTTAGTGTCCACG-30 and 50- AGAACCAGGTGTAGGATTGCGGA-30),
Il9/RBP-Jk (50- TGTTGACTGGTGAGAGGCAGGGT-30 and 50- ACGTGGACAC
TAAGCTGTCTGGA-30), Gata3/RBP-Jk (50-GAAGGCGTCATCCCCTCT-30 and
50-AAGTTACTTGGAACTTTTAAGAAAGG-30), Gata3/Smad3 (50-ATATGATGA
GTCTTCTCTGGGACTT-30 and 50-AAGGCACAGAGACCCAGTTT-30).
Retroviral Transduction
Total CD4+ T cells from NICD1fl/fl transgenic or Notch1fl/flNotch2fl/fl mice
were transduced with a MSCV-based retroviral vector (RV) expressing Cre.
The RV particles were produced by cotransfecting the plasmids encoding
for gag-pol, the ecotropic envelope, and the retroviral vector with Effectene
(QIAGEN) into the Phoenix packaging cells. RV supernatant was harvested
48 hr after transfection and centrifuged prior to use. CD4+CD62L+ T cells iso-
lated by magnetic-activated cell sorting (MACS) from Notch1fl/flNotch2fl/fl
or NICD1fl/fl mice were activated with anti-CD3 and anti-CD28 for 24 hr,
retroviral supernatant was added to the cells together with polybrene
(8 mg/ml), and cells were incubated at 37C. After incubation, live cells were
sorted with the Dead Cell Removal Kit (Miltenyi) and equal numbers of cells
were expanded for an additional 48–72 hr in the presence of IL-2 or as other-
wise indicated.
Luciferase Reporter Assay and Site-Directed Mutagenesis
Reporter vector coding for the Firefly Luciferase under the control of the Il9
promoter encompassing nucleotides 5023 to +31 bp was amplified from
genomic DNA by PCR with 50-GCTACAGGCCTGGGTGACTGC-30 and 50-TAT
GCCTCTGATTTATTTTACTTG-30 as primers, which was verified by DNA
sequencing and was cloned into the promoterless pGL3 Basic luciferase
reporter gene vector (Promega). Reporter assays were carried out as
described previously (Stassen et al., 2007). In brief, 293T cells were trans-
fected with 0.4 mg of the reporter vector coding for the firefly luciferase
(pGL3 basic; Promega) under the control of the Il9 promoter and with 0.8 mg
of the NICD1 (Schroeter et al., 1998), RBP-Jk (Jarriault et al., 1995) or
Smad3 (Kretzschmar et al., 1999) plasmids with the Effectene kit (QIAGEN).
Cells were cultured for 48 hr before harvesting and the relative Il9 promoter
activity wasmeasuredwith Promega kit in accordancewith themanufacturer’s
instructions. For assays in primary T cells, CD4+ T cells were prepared accord-
ing to the Amaxa kit and 10 mg of Il9 reporter vector were transfected by elec-
troporation with different combination of 2.5 mg of RBP-Jk, NICD1, and Smad3
constructs. After Amaxa nucleofection, cells were stimulated with anti-CD3/
CD28 for 2 days and then activated with 300 ng/ml Ionomycin and 20 ng/ml
PMA for 4–6 hr, and the relative Il9 promoter activity was measured with
Promega kit. Site-directed mutagenesis of the RBP-Jk and Smad3-binding
sites in the Il9 promoter was performed with the QuikChange Site-Directed
Mutagenesis Kit (Stratagene) in accordance with the manufacturer’s instruc-
tions. The following primers were used: RBP-Jk (50-ctcagaatttggctgtacagtga
aaaaaagagagtcttcttagagg-30 and antisense 50-cctctaagaagactctctttttttcactgt
acagccaaattctgag-30) and Smad3 (50-ttagtgctgcatgagttacaacctgactcttttgagtc
tggc-30 and antisense 50-gccagactcaaaagagtcaggttgtaactcatgcagcactaa-30).
Reporter constructs derived from these mutant versions of the Il9 promoter
were named as pGL3-Il9-RPB-Jk mutant and pGL3-Il9-Smad3 mutant.
Statistical Analysis
The Mann-Whitney t test was used for clinical disease analysis. Statistical
evaluations of cytokine production, luciferase activity and cell frequency
measurements were performed with the unpaired Student’s t test. Values of
p < 0.05 were considered statistically significant.
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